Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo

Soo Young Kim; Seok Mo Kim; Hojin Chang; Hang Seok Chang; Cheong Soo Park; Yong Sang Lee

doi:10.1002/hed.26431

Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo

Soo Young Kim, Seok Mo Kim, Hojin Chang, Hang Seok Chang, Cheong Soo Park, Yong Sang Lee

Department of Surgery

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Background: This study aimed to investigate the antitumor activity of paclitaxel with radiation and sorafenib in anaplastic thyroid cancer (ATC) cells in vitro and in vivo. Methods: The 8505C ATC cell line was exposed to radiation, sorafenib, and paclitaxel each or in combination. The effects of combined treatment on the cell cycle and intracellular signaling pathways were assessed using flow cytometry and western blot analysis. An ATC cell line xenograft model was used to examine antitumor activity in vivo. Results: Radiation, paclitaxel plus sorafenib synergistically decreased cell viability in ATC cells and significantly increased apoptotic cell death. The combination of paclitaxel, sorafenib with radiation reduced the antiapoptotic factor in ATC. This combination therapy significantly reduced the tumor volume and increased survival in the ATC xenograft model. Conclusions: These results suggest that the combination of radiation and paclitaxel plus sorafenib has significant anticancer activity in preclinical models.

Original language	English
Pages (from-to)	3678-3684
Number of pages	7
Journal	Head and Neck
Volume	42
Issue number	12
DOIs	https://doi.org/10.1002/hed.26431
Publication status	Published - 2020 Dec

Bibliographical note

Funding Information:
The authors thank Dr Seung Won Kim, Dr Ki Chung Park for critical brainstorming and Dr Kyung Hwa Choi for assistance with tumor cell isolation from patient specimen. This work was supported by a faculty research grant from Yonsei University College of Medicine for 6-2016-0123 and the Brain Korea 21 Project for Medical Science, Yonsei University.

Funding Information:
The authors thank Dr Seung Won Kim, Dr Ki Chung Park for critical brainstorming and Dr Kyung Hwa Choi for assistance with tumor cell isolation from patient specimen. This work was supported by a faculty research grant from Yonsei University College of Medicine for 6‐2016‐0123 and the Brain Korea 21 Project for Medical Science, Yonsei University.

Publisher Copyright:
© 2020 Wiley Periodicals LLC

All Science Journal Classification (ASJC) codes

Otorhinolaryngology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.26431

Cite this

@article{48a7de5571274bc087652e0f873077b3,

title = "Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo",

abstract = "Background: This study aimed to investigate the antitumor activity of paclitaxel with radiation and sorafenib in anaplastic thyroid cancer (ATC) cells in vitro and in vivo. Methods: The 8505C ATC cell line was exposed to radiation, sorafenib, and paclitaxel each or in combination. The effects of combined treatment on the cell cycle and intracellular signaling pathways were assessed using flow cytometry and western blot analysis. An ATC cell line xenograft model was used to examine antitumor activity in vivo. Results: Radiation, paclitaxel plus sorafenib synergistically decreased cell viability in ATC cells and significantly increased apoptotic cell death. The combination of paclitaxel, sorafenib with radiation reduced the antiapoptotic factor in ATC. This combination therapy significantly reduced the tumor volume and increased survival in the ATC xenograft model. Conclusions: These results suggest that the combination of radiation and paclitaxel plus sorafenib has significant anticancer activity in preclinical models.",

author = "Kim, {Soo Young} and Kim, {Seok Mo} and Hojin Chang and Chang, {Hang Seok} and Park, {Cheong Soo} and Lee, {Yong Sang}",

note = "Funding Information: The authors thank Dr Seung Won Kim, Dr Ki Chung Park for critical brainstorming and Dr Kyung Hwa Choi for assistance with tumor cell isolation from patient specimen. This work was supported by a faculty research grant from Yonsei University College of Medicine for 6-2016-0123 and the Brain Korea 21 Project for Medical Science, Yonsei University. Funding Information: The authors thank Dr Seung Won Kim, Dr Ki Chung Park for critical brainstorming and Dr Kyung Hwa Choi for assistance with tumor cell isolation from patient specimen. This work was supported by a faculty research grant from Yonsei University College of Medicine for 6‐2016‐0123 and the Brain Korea 21 Project for Medical Science, Yonsei University. Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",

year = "2020",

month = dec,

doi = "10.1002/hed.26431",

language = "English",

volume = "42",

pages = "3678--3684",

journal = "Head and Neck Surgery",

issn = "1043-3074",

publisher = "John Wiley and Sons Inc.",

number = "12",

}

TY - JOUR

T1 - Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo

AU - Kim, Soo Young

AU - Kim, Seok Mo

AU - Chang, Hojin

AU - Chang, Hang Seok

AU - Park, Cheong Soo

AU - Lee, Yong Sang

N1 - Funding Information: The authors thank Dr Seung Won Kim, Dr Ki Chung Park for critical brainstorming and Dr Kyung Hwa Choi for assistance with tumor cell isolation from patient specimen. This work was supported by a faculty research grant from Yonsei University College of Medicine for 6-2016-0123 and the Brain Korea 21 Project for Medical Science, Yonsei University. Funding Information: The authors thank Dr Seung Won Kim, Dr Ki Chung Park for critical brainstorming and Dr Kyung Hwa Choi for assistance with tumor cell isolation from patient specimen. This work was supported by a faculty research grant from Yonsei University College of Medicine for 6‐2016‐0123 and the Brain Korea 21 Project for Medical Science, Yonsei University. Publisher Copyright: © 2020 Wiley Periodicals LLC

PY - 2020/12

Y1 - 2020/12

N2 - Background: This study aimed to investigate the antitumor activity of paclitaxel with radiation and sorafenib in anaplastic thyroid cancer (ATC) cells in vitro and in vivo. Methods: The 8505C ATC cell line was exposed to radiation, sorafenib, and paclitaxel each or in combination. The effects of combined treatment on the cell cycle and intracellular signaling pathways were assessed using flow cytometry and western blot analysis. An ATC cell line xenograft model was used to examine antitumor activity in vivo. Results: Radiation, paclitaxel plus sorafenib synergistically decreased cell viability in ATC cells and significantly increased apoptotic cell death. The combination of paclitaxel, sorafenib with radiation reduced the antiapoptotic factor in ATC. This combination therapy significantly reduced the tumor volume and increased survival in the ATC xenograft model. Conclusions: These results suggest that the combination of radiation and paclitaxel plus sorafenib has significant anticancer activity in preclinical models.

AB - Background: This study aimed to investigate the antitumor activity of paclitaxel with radiation and sorafenib in anaplastic thyroid cancer (ATC) cells in vitro and in vivo. Methods: The 8505C ATC cell line was exposed to radiation, sorafenib, and paclitaxel each or in combination. The effects of combined treatment on the cell cycle and intracellular signaling pathways were assessed using flow cytometry and western blot analysis. An ATC cell line xenograft model was used to examine antitumor activity in vivo. Results: Radiation, paclitaxel plus sorafenib synergistically decreased cell viability in ATC cells and significantly increased apoptotic cell death. The combination of paclitaxel, sorafenib with radiation reduced the antiapoptotic factor in ATC. This combination therapy significantly reduced the tumor volume and increased survival in the ATC xenograft model. Conclusions: These results suggest that the combination of radiation and paclitaxel plus sorafenib has significant anticancer activity in preclinical models.

UR - http://www.scopus.com/inward/record.url?scp=85090306591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090306591&partnerID=8YFLogxK

U2 - 10.1002/hed.26431

DO - 10.1002/hed.26431

M3 - Article

C2 - 32896015

AN - SCOPUS:85090306591

SN - 1043-3074

VL - 42

SP - 3678

EP - 3684

JO - Head and Neck Surgery

JF - Head and Neck Surgery

IS - 12

ER -

Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this